financetom
Business
financetom
/
Business
/
Market Chatter: ArcelorMittal, Nippon Steel JV Warns Import Curbs Could Cut India Steel Production, Delay Expansion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: ArcelorMittal, Nippon Steel JV Warns Import Curbs Could Cut India Steel Production, Delay Expansion
Mar 5, 2025 1:40 PM

04:14 PM EST, 03/05/2025 (MT Newswires) -- ArcelorMittal ( MT ) warned that steel production at its India joint venture with Nippon Steel could be significantly reduced due to restrictions on low-ash metallurgical coke imports, Reuters reported, citing a private letter to India's Minister of Commerce and Industry.

The joint venture's CEO, Dilip Oommen, said in the letter dated Feb. 19 that the joint venture may need to scale back production from April or shut down its blast furnace operations by June unless it secures additional coke beyond the country-specific import quotas imposed by India starting January 1.

"We are heading for a difficult and uncertain period," Oommen wrote in the letter seen by Reuters.

The import curbs, aimed at protecting domestic coke producers, have faced opposition from major steelmakers, who argue that domestic supply does not meet their quality requirements. ArcelorMittal India JV also said the restrictions could delay its $9 billion expansion plan in India, which includes increasing capacity to 40 million metric tons annually by 2035.

ArcelorMittal ( MT ) and Nippon Steel did not immediately respond to a request from MT Newswires seeking comment on Wednesday.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 33.62, Change: +3.36, Percent Change: +11.09

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Synaptics Expands Taiwan Presence, Operations
Synaptics Expands Taiwan Presence, Operations
Oct 23, 2024
03:57 AM EDT, 10/23/2024 (MT Newswires) -- Synaptics ( SYNA ) said late Tuesday it has expanded in the Taiwanese city of Hsinchu, making Taiwan the company's largest base of personnel worldwide. The company said the expansion gives it headroom to grow both its essential operations and engineering expertise. The facilities will house the team developing its AI-enabled devices for...
Finance guide could spur extra $200 billion for sustainable development, JPMorgan says
Finance guide could spur extra $200 billion for sustainable development, JPMorgan says
Oct 23, 2024
* Impact disclosure guidance released by Taskforce * Group chaired by JPMorgan ( JPM ), Natixis * Aims to help countries, companies raise impact finance By Karin Strohecker and Simon Jessop WASHINGTON, Oct 23 (Reuters) - A new guide for countries and companies seeking financing for activities that have a positive and verifiable social or environmental impact could unlock an...
--Mueller Water Products Increases Quarterly Dividend to $0.067 per Share From $0.064; Payable Nov. 20 to Shareholders of Record on Nov. 8
--Mueller Water Products Increases Quarterly Dividend to $0.067 per Share From $0.064; Payable Nov. 20 to Shareholders of Record on Nov. 8
Oct 23, 2024
04:03 AM EDT, 10/23/2024 (MT Newswires) -- Price: 22.01, Change: -0.06, Percent Change: -0.27 ...
Alto Neuroscience Says Phase 2b Study in Major Depressive Disorder Fails to Meet Primary Endpoint
Alto Neuroscience Says Phase 2b Study in Major Depressive Disorder Fails to Meet Primary Endpoint
Oct 23, 2024
04:06 AM EDT, 10/23/2024 (MT Newswires) -- Alto Neuroscience ( ANRO ) said late Tuesday a phase 2b study of ALTO-100 in patients with major depressive disorder failed to meet its primary endpoint compared with placebo. Treatment with ALTO-100 did not demonstrate improvement in depressive symptoms compared to placebo in patients with a memory-based cognitive biomarker, Alto Neuroscience ( ANRO...
Copyright 2023-2025 - www.financetom.com All Rights Reserved